Dalazatide, a Kv1.3 channel inhibitor currently in clinical trials, has been reported to reduce inflammatory cytokines such as IFN-γ, IL-17, and TNF–α in CD4+ and CD8+ T cells from patients with systemic lupus erythematosus (SLE) (68). The gene discussed is CD8A; the disease is systemic lupus erythematosus.